First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin
Purpose: The primary objective of this study is, to determine the safety, tolerability, maximum tolerated dose (MTD) or maximum feasible dose of BAY2287411 Injection in patients with epithelioid malignant mesothelioma and serous ovarian cancer
Read MoreImmunotherapy May Help Extend the Lives of Lung Cancer and Mesothelioma Patients
Immunotherapy is revolutionizing the health care industry by adding extra years of life to people with lung cancer. A few years ago it was rare for patients with an advanced stage of this disease to live past two years but today it has become more common to do so. Immunotherapy treatment works by boosting immune…
Read MoreImmunotherapy Treatment Durvalumab Enters Phase II Clinical Trial
While there is no cure for mesothelioma, those who are able to withstand surgery in general may have a better chance of survival, as the cancer is being physically removed. However, mesothelioma is a difficult cancer and often surgery is not an option, and the cancer is unresectable. The success of immunotherapy treatments for cancer…
Read MoreStepped Palliative Care Versus Early Integrated Palliative Care in Patients With Advanced Lung Cancer (STEP PC)
Purpose: This research study is evaluating ways to provide palliative care to patients who have recently been diagnosed with lung cancer
Read MoreUnderstanding Asbestos Exposure and Mesothelioma
Exposure to asbestos does not always mean that the individual exposed will develop an asbestos-caused disease or cancer. However, there is no safe level of asbestos exposure, and if you have encountered friable asbestos fibers unprotected, you are at risk of developing lung cancer, asbestosis, or mesothelioma. While we know today that asbestos exposure is…
Read MoreAsbestos Exposure Documentary Makes Debut At International Film Festival
Last weekend at the San Luis Obispo International Film Festival, a 75- minute documentary about asbestos exposure and mesothelioma made its world debut, highlighting the aggressive and often fatal diseases associated with asbestos exposure, and how it has affected so many lives. After mesothelioma claimed the life of their grandmother in 2012, cousins Conor Lewis…
Read MoreBiomarker CD47 as a Successful Diagnostic and Treatment Tool
Survival rates for diffuse mesothelioma are notoriously low with the median survival ranging between 12 to 22 months. A contributing factor to treatment being ineffective is that the disease if often in the advanced stages by the time it is noticed and diagnosed. Early detection may be a key factor in fighting this illness effectively,…
Read MoreEpithelioid Mesothelioma And Reactive Mesothelial Hyperplasia
The type of mesothelioma can be based upon where the cancer is located in the body, but it can also be based upon cell type – meaning, which cell has turned cancerous. The body has many different types of cells including epithelial, which make up the lining of the mesothelium (where mesothelioma develops). When these…
Read MoreAsbestos Cancer Risk Measured by Fiber Length
Since asbestos was used for decades in thousands of products ranging from attic insulation to woven oven mitts, it is hard to imagine that this versatile material is actually a naturally occurring mineral, composed of chemical compounds bundled into fibers. Found in serpentine, mafic, and altered ultramafic rocks, asbestos is divided into two groups – serpentine and…
Read MoreMesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma
Purpose: Mesothelioma is cancer of the tissue that lines some organs. A new drug, LMB-100, may bind to a protein on mesothelioma tumors and kill cancer cells. But sometimes the body makes antibodies that reduce how well LMB-100 works. Researchers want to see if adding the drug SEL-110 to LMB-100 will prevent these antibodies from forming.
Read More